Motilide compounds

Details Motilide compounds Motilide compounds

2001-02-15

2003-05-13

Peselev, Elli (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S007200, C536S007400

Reexamination Certificate

active

06562795

ABSTRACT:

This application claims priority to U.S. Provisional Application No. 60/183,338, filed Feb. 18, 2000, entitled MOTILIDE COMPOUNDS by inventors Gary Ashley, Mark Burlingame, Chris Carreras, and Daniel Santi, which is incorporated herein in its entirety by reference.
BACKGROUND
The present invention provides novel prokinetic agents with superior pharmacological and pharmacokinetic properties for the treatment of gastrointestinal motility disorders. The invention relates to the fields of chemistry, medicinal chemistry, medicine, molecular biology, and pharmacology.
Gastrointestinal (“GI”) motility regulates the orderly movement of ingested material through the gut to insure adequate absorption of nutrients, electrolytes and fluids. Appropriate transit through the esophagus, stomach, small intestine and colon depends on regional control of intraluminal pressure and several sphincters that regulate forward movement and prevent back-flow of GI contents. The normal GI motility pattern may be impaired by a variety of circumstances including disease and surgery.
Disorders of gastrointestinal motility include, for example, gastroparesis and gastroesophageal reflux disease (“GERD”). Gastroparesis is the delayed emptying of stomach contents. Symptoms of gastroparesis include stomach upset, heartburn, nausea, and vomiting. Acute gastroparesis may be caused by, for example, drugs (e.g., opiates), viral enteritis, and hyperglycemia, and is usually managed by treating the underlying disease rather than the motility disorder. The most common causes of chronic gastroparesis are associated with long standing diabetes or idiopathic pseudo-obstruction, often with so-called “non-ulcer” or “functional” dyspepsia.
GERD refers to the varied clinical manifestations of reflux of stomach and duodenal contents into the esophagus. The most common symptoms are heartburn and dysphasia; blood loss may also occur from esophageal erosion. GERD may be associated with low tone and inappropriate relaxation of the lower esophageal sphincter and occurs with gastroparesis in about 40% of cases. In most cases, GERD appears to be treatable with agents that reduce the release of acidic irritant by the stomach (e.g., Prilosec) or agents that increase the tone of the lower esophageal sphincter (e.g., cisapride). Other examples of disorders whose symptoms include impaired gastrointestinal motility are anorexia, gall bladder stasis, postoperative paralytic ileus, scleroderma, intestinal pseudoobstruction, gastritis, emesis, and chronic constipation (colonic inertia).
These GI disorders are generally treated with prokinetic agents that enhance propulsive motility. Motilides are macrolide compounds such as erythromycin and its derivatives that are agonists of the motilin receptor. Evidence of the potential clinical utility of motilides includes their ability to induce phase III of Migrating Motor Complexes (“MMC”). MMC refers to the four phases (I-IV) of electrical activity displayed by the stomach and small intestine in the fasting state. Muscular contraction occurs in phases III and IV which coincide with a peristaltic wave that propels enteric contents distally during fasting. Other clinically relevant effects include: increase in esophageal peristalsis and LES pressure in normal volunteers and patients with GERD; acceleration of gastric emptying in patients with gastric paresis; and stimulation of gallbladder contractions in normal volunteers, patients after gallstone removal, and diabetics with autonomic neuropathy.
The discovery of motilides was serendipitous. Since the 1950's, erythromycin A 1 has been known to cause GI side effects such as nausea, vomiting, and abdominal discomfort. These effects are now largely explained by the motilin agonist activity of erythromycin A and an acid catalyzed degradation production, 8,9-anhydro-6,9-hemiacetal 2, which is also known as the enol ether form.
As illustrated by Scheme A, erythromycin A 1 undergoes an acid catalyzed rearrangement in the stomach to form the enol ether 2 which is then further degraded into the spiroketal 3.Both erythromycin A and the enol ether are motilin agonists but the spiroketal is not. Because the enol ether is approximately ten fold more potent as a motilin agonist than erythromycin A and does not also possess antimicrobial activity, the potential clinical uses of enol ether derivatives as prokinetic agents are being investigated.
Enol ether erythromycin derivatives under clinical investigation include EM-523 (4); EM-574 (5); LY267,108 (6); GM-611 (7); and ABT-229 (8) whose structures are shown below. See U.S. Pat. Nos. 5,578,579; 5,658,888; 5,922,849; 6,077,943; and 6,084,079 which are all incorporated herein by reference.
Other motilides of potential interest include lactam enol ethers and lactam epoxide derivatives. See also U.S. Pat. Nos. 5,712,253; 5,523,401; 5,523,418; 5,538,961; 5,554,605 which are incorporated herein by reference.
In general, these and other previously disclosed macrolides are synthetically accessible compounds that are derived from erythromycin A or B. Because nature has not optimized the erythromycin structure for its prokinetic activity, it is likely that the potency of motilide agonists could be greatly enhanced. Compounds resulting from such efforts could be of significant benefit in the treatment of wide variety of diseases and conditions. The present invention provides such compounds.
SUMMARY
The present invention provides novel macrolide compounds with superior pharmacological and pharmacokinetic properties for the treatment of gastrointestinal motility disorders. In one embodiment, the present invention provides compounds of the formulas
wherein:
R is hydroxyl or methoxy;
R
1
is selected from the group consisting of hydrogen, hydroxyl, halide, NH
2
, OR
9
,
 and
 where R
9
is C
1
-C
10
alkyl, C
2
-C
10
alkenyl, C
2
-C
10
alkynyl, aryl or heteroaryl and R
10
and R
11
are each independently hydrogen, C
1
-C
10
alkyl, C
2
-C
10
alkenyl, C
2
-C
10
alkynyl, or aryl;
R
2
and R
3
are each independently selected from the group consisting of hydrogen, C
1
-C
10
alkyl, C
2
-C
10
alkenyl, C
2
-C
10
alkynyl, aryl, alkylaryl, alkenylaryl, alkynylaryl or R
2
and R
3
together form a cycloalkyl or a cycloaryl moiety;
R
4
is hydrogen or methyl;
R
5
is hydrogen, hydroxyl, oxo, or together with R
6
and the carbons to which they are attached form a cyclic carbonate;
R
6
is hydrogen, hydroxyl, OR
12
where R
12
is C
1
-C
10
alkyl, C
2
-C
10
alkenyl, C
2
-C
10
alkynyl, or together with R
5
and the carbons to which they are attached form a cyclic carbonate;
R
7
is methyl, C
3
-C
10
alkyl, C
2
-C
10
alkenyl, C
2
-C
10
alkynyl, alkylaryl, alkenylaryl, alkynylaryl, amidoalkylaryl, amidoalkenylaryl, or amidoalkynylaryl;
R
8
is C
1
-C
10
alkyl, C
2
-C
10
alkenyl, C
2
-C
10
alkynyl, alkylaryl, alkenylaryl, alkynylaryl, amidoalkylaryl, amidoalkenylaryl, or amidoalkynylaryl; and,
x is a single or a double bond. These and other embodiments, modes, and aspects of the invention are described in more detail in the following description, the examples, and claims set forth below.


REFERENCES:
patent: 4677097 (1987-06-01), Omura et al.
patent: 4916138 (1990-04-01), Ueda et al.
patent: 5523401 (1996-06-01), Freiberg et al.
patent: 5523418 (1996-06-01), Freiberg et al.
patent: 5538961 (1996-07-01), Freiberg et al.
patent: 5554605 (1996-09-01), Freiberg et al.
patent: 5578579 (1996-11-01), Lartey et al.
patent: 5658888 (1997-08-01), Koga et al.
patent: 5672491 (1997-09-01), Khosla et al.
patent: 5712146 (1998-01-01), Khosla et al.
patent: 5712253 (1998-01-01), Lartey et al.
patent: 5830750 (1998-11-01), Khosla et al.
patent: 5843718 (1998-12-01), Khosla et al.
patent: 5854407 (1998-12-01), Harada et al.
patent: 5922849 (1999-07-01), Premchandran et al.
patent: 5962290 (1999-10-01), Khosla et al.
patent: 6066721 (2000-05-01), Khosla et al.
patent: 6077943 (2000-06-01), Omura et al.
patent: 6084079 (2000-07-01), Keyes et al.
patent: WO 93/13780 (1993-07-01), None
patent: WO 97/02358 (1997-01-01), None
pate

Affiliated with

Also associated with

Rating

Motilide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Motilide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Motilide compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3003865